Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression

Digestive and Liver Disease

Volumn 42, Issue 4, 2010, Pages 297-303

  Lionetti, Raffaella ^a   Tisone, Giuseppe ^a   Palmieri, Giampiero ^a   Almerighi, Cristiana ^a   Anselmo, Alessandra ^a   Tariciotti, Laura ^a   Lenci, Ilaria ^a   De Luca, Linda ^a   Monaco, Andrea ^a   Angelico, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Disease recurrence; Grading; Graft; Immunosuppression; Staging

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN A; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; RISK REDUCTION; TREATMENT DURATION;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN;

EID: 77649191026     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.08.008     Document Type: Article

References (49)

1. Zarski J.P., Mc Hutchinson J., Bronowicki J.P., et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 38 (2003) 307-314
2. Ghany M.G., Kleiner D.E., Alter H., et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 124 (2003) 97-104
3. Sanchez Fueyo A., Restrepo J., Quinto L., et al. Impact of recurrence of HCV infection after liver transplantation on the long term viability of graft. Transplantation 73 (2002) 56-63
4. Berenguer N., Ferrell L., Watson J., et al. HCV-related fibrosis progression after liver transplantation: increase in recent years. J Hepatol 32 (2000) 673-684
5. Gane E., Portmann B., Naoumov N., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334 (1996) 815-820
6. Poynard T., McHutchinson J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis. Gastroenterology 122 (2002) 1303-1313
7. Zeuzem S., Feinman V., Rasenack J., et al. Peginterferon alfa 2a in patients with chronic hepatitis C. N Eng J Med 23 (2000) 1666-1672
8. Heathcote J., Shiffman M., Graham W., et al. Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Eng J Med 23 (2000) 1673-1680
9. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 347 (2002) 975-982
10. Manns M.P., McHutchinson J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
11. National institute of health consensus development conference statement: management of hepatitis C. Hepatology 36 (2002) S1-S15
12. Berenguer M. Natural history of recurrent hepatitis C. Liver Transplant 10 (2002) S14-18
13. Berenguer M., Aguilera V., Prieto M., et al. Delayed onset of severe hepatitis C related liver damage following liver transplantation: a matter of concern?. Liver Transplant 9 (2003) 1152-1158
14. Dumortier J., Scoazec J.Y., Chevallier P., et al. Treatment of recurrent hepatitis C after liver transplantation: pilot study of peginterferon alfa 2b and ribavirin combination. J Hepatol 4 (2004) 669-674
15. Rodriguez Luna H., Khatib A., Sharma P., et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha and ribavirin: an open-label study. Transplantation 77 (2004) 190-194
16. Chalasani N., Manzarbeitia C., Ferenci P., et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41 (2005) 289-298
17. Samuel D., Bizollon T., Feray C., et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation. A randomized study. Gastroenterology 124 (2003) 642-650
18. Abdelmalek M.F., Firpi R., Soldevila-Pico C., et al. Sustained virological response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplant 10 (2004) 199-207
19. Bizollon T., Palazzo U., Ducerf C., et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 26 (1997) 500-504
20. Alberti A.B., Belli L.S., Airoldi A., et al. Combined therapy with interferon and low dose of ribavirin in post-transplantation recurrent hepatitis C: a pragmatic study. Liver Transplant 7 (2001) 870-876
21. Shakil A.O., Mc Guire B., Crippin J., et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 36 (2002) 1253-1258
22. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplant 8 (2002) 1000-1006
23. Ross A.S., Bham A.K., Pascual M., et al. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 18 (2002) 166-173
24. Neff G.W., Montalbano M., O'Brien C.B., et al. Treatment of established recurrent hepatitis C in liver transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transplantation 78 (2004) 1303-1307
25. Feray C., Samuel D., Gigou M., et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 22 (1995) 1084-1089
26. Saab S., Kalmaz D., Gajjar N., et al. Outcome of acute rejection after interferon therapy in liver transplant recipients. Liver Transplant 10 7 (2004) 859-867
27. Kuo A., and Terrault N.A. Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?. J Hepatology 46 (2007) 359-361
28. Pawlotsky J.M., Dahari H., Neumann A.U., et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126 3 (2004) 703-714
29. Lau N., Tam R., Liang J., et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 (2002) 1002-1009
30. Tam R., Pai B., Bard J., et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 30 (1999) 376-382
31. Vollmer J., Rankin R., Hartmann H., et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother 48 (2004) 2314-2317
32. Zhang Y., Jamaluddin M., Wang S., et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 77 (2003) 5933-5947
33. Dixit N.M., Layden J., Layden T., et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432 (2004) 922-924
34. Hoofnagle J., Ghany M., Kleiner D., et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 38 (2003) 66-74
35. Patel K., Dev A., Muir A., and McHutchison J.G. Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?. Hepatology 38 21 (2003) 24
36. Bizollon T., Ahmed S.N., Radenne S., et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained virological response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 52 (2003) 283-287
37. Brok J., Gluud L.L., and Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane hepato-biliary group systematic review and meta-analysis of randomized trial. Am J Gastroenterol 101 4 (2006) 842-847
38. Colloredo G., Guido M., Sonzogni A., et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39 (2003) 239-244
39. Demetris A.J., and Ruppert K. Pathologist's perspective on liver needle biopsy size?. J Hepatol 39 (2003) 275-277
40. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
41. Scheuer P.J. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 38 (2003) 1356-1358
42. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
43. Neumann P., Berg T., Bahra M., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004) 830-836
44. Angelico M., Petrolati A., Lionetti R.G., et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 46 (2007) 1009-1017
45. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transplant 9 (2003) S28-S34
46. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol 42 (2005) 448-479
47. Baiocchi L., Angelico M., Petrolati A., et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant 8 3 (2008) 673-678
48. Tisone G., Orlando G., Cardillo A., et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 44 (2006) 702-709
49. Kamar N., Chatelut E., Manolis E., et al. Rivabirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 43 (2004) 140-146